Quantessence Capital’s AbbVie ABBV Stock Holding History

Quantessence Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,715	Closed	-$590K	–	76
2026 Q1	$590K	Buy	+2,715	New	+$602K	2.88%	6
2025 Q2	–	Sell	-10,600	Closed	-$2.22M	–	183
2025 Q1	$2.22M	Buy	+10,600	New	+$2.06M	0.56%	38

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Quantessence Capital's ABBV Position: Q2 2026 in Review

Quantessence Capital sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 2,715 shares — an estimated $590K sold.

Quantessence Capital first reported a position in ABBV in Q1 2025 and held it in 2 quarters. The position peaked at $2.22M in Q1 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Quantessence Capital reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Quantessence Capital sold 2,715 AbbVie shares in Q2 2026, an estimated $590K.
Quantessence Capital first reported a position in AbbVie in Q1 2025 and held it in 2 quarters.
Quantessence Capital's AbbVie position peaked at $2.22M in Q1 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Quantessence Capital's 13F filing for Q2 2026, filed 14 Aug 2026.